
|Videos|June 16, 2017
The Complexity of the PARP Inhibitor Landscape in Ovarian Cancer
Author(s)Douglas A. Levine, MD
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Divison of Gynecologic Oncology, NYU Langone Medical Center, discusses the impact of PARP inhibitors on the landscape of ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































